J. Yang

发表

Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans

S. Libutti, S. Bacharach, N. Freedman, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

F. Marincola, S. Rosenberg, P. Hwu, 1998, Nature Medicine.

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

S. Rosenberg, R. Morgan, J. Yang, 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis.

M. Merino, S. Rosenberg, R. Morgan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

M. Raffeld, P. Duray, S. Rosenberg, 2002, Science.

Adoptive cell transfer: a clinical path to effective cancer immunotherapy

S. Rosenberg, R. Morgan, J. Yang, 2008, Nature Reviews Cancer.

Toxicities of Immunotherapy for the Practitioner.

M. Atkins, J. Yang, J. Weber, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine

S. Rosenberg, J. Yang, N. Restifo, 2010, Journal of immunotherapy.

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

S. Rosenberg, J. Yang, S. Turcotte, 2014, Science.

Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes

S. Rosenberg, R. Morgan, J. Yang, 2006, Science.

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.

S. Rosenberg, D. Citrin, J. Yang, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

S. Steinberg, S. Rosenberg, D. Citrin, 2011, Clinical Cancer Research.

Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma.

S. Steinberg, S. Rosenberg, D. Citrin, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma?

S. Rosenberg, J. Yang, R. Sherry, 2014, Nature Reviews Clinical Oncology.

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

M. Merino, S. Rosenberg, R. Morgan, 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Tongguang Wang, Dolores J. Schendel, Richard A. Morgan, 2013, Journal of immunotherapy.

Landscape of Tumor Antigens in T Cell Immunotherapy

S. Ilyas, J. Yang, Sadia Ilyas, 2015, The Journal of Immunology.

Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

Sung-Liang Yu, Ker-Chau Li, Min-Liang Kuo, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Seth M Steinberg, S. Steinberg, Helen X. Chen, 2003, The New England journal of medicine.

MISSION Trial - A phase III, multi-center, placebo-controlled trial of sorafenib in patients with relapsed or refractory predominantly non-squamous NSCLC after 2 or 3 previous treatment regimens.

H. Wakelee, E. Smit, T. Mok, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Cancer immunotherapy: moving beyond current vaccines

S. Rosenberg, J. Yang, N. Restifo, 2004, Nature Medicine.

Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma

S. Steinberg, S. Rosenberg, J. Yang, 2005, The Journal of Immunology.

First‐Line Afatinib versus Chemotherapy in Patients with Non–Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

L. Sequist, K. O'Byrne, T. Mok, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases

S. Rosenberg, J. Butman, J. Yang, 2018, Journal of immunotherapy.

A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

F. Marincola, S. Rosenberg, P. Hwu, 2002, Journal of immunotherapy.

Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.

S. Rosenberg, P. Hwu, J. Yang, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma

S. Rosenberg, D. Citrin, J. Yang, 2010, Clinical Cancer Research.

Abstract LB-175: Tumor regression in patients with metastatic synovial sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

S. Rosenberg, R. Morgan, J. Yang, 2010 .

Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction1

C. Klebanoff, J. Yang, N. Restifo, 2004, The Journal of Immunology.

Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma

S. Rosenberg, J. Yang, P. Robbins, 1997, The Journal of experimental medicine.

Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2017, Current Oncology Reports.

Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

S. Rosenberg, J. Yang, A. Maker, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

F. Marincola, S. Rosenberg, P. Hwu, 2001, Journal of immunotherapy.

Immunization against Endogenous Retroviral Tumor-associated Antigens 1

Willem, P. Hwu, J. Yang, 2001 .

Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens

S. Rosenberg, P. Hwu, J. Yang, 2003, Journal of immunotherapy.

Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.

S. Rosenberg, P. Hwu, J. Yang, 2003, Human gene therapy.

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis.

S. Rosenberg, K. Csaky, J. Yang, 2004, Journal of immunotherapy.

Immunization of HLA-A*0201 and/or HLA-DPβ1*04 Patients with Metastatic Melanoma Using Epitopes from the NY-ESO-1 Antigen

S. Rosenberg, J. Yang, S. Topalian, 2004, Journal of immunotherapy.

Anti-CD19 CAR T Cells Administered after Low-Dose Chemotherapy Can Induce Remissions of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma

S. Rosenberg, C. Klebanoff, J. Yang, 2014 .

Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment?

J. Yang, 2019, The Lancet. Oncology.

Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.

I. Marschner, T. Mok, J. Yang, 2019, Future oncology.

Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non–Small Cell Lung Cancer

P. Jänne, T. Mitsudomi, S. Ramalingam, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers.

J. Gartner, S. Rosenberg, J. Yang, 2022, Cancer cell.

Immunotherapy for renal cell cancer.

J. Yang, R. Childs, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers

J. Yang, N. Restifo, Zhiya Yu, 2016, Clinical Cancer Research.

Study on Adoptive Immunotherapy Using Gene-Modified TCells for Ovarian Cancer

S. Rosenberg, P. Hwu, S. Canevari, 2006 .

A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen

S. Rosenberg, P. Hwu, J. Yang, 1998, Nature Medicine.

Audiovestibular Dysfunction Associated with Adoptive Cell Immunotherapy for Melanoma

S. Rosenberg, C. Van Waes, R. Morgan, 2011, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

regression and targets normal tissues expressing cognate antigen Gene therapy with human and mouse T-cell receptors mediates cancer

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009 .

Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis

S. Rosenberg, I. Lowy, J. Yang, 2007, Journal of immunotherapy.

Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.

S. Rosenberg, J. Yang, R. Sherry, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors.

Jih-Hsiang Lee, J. Shih, Hsuan-Yu Chen, 2019, The oncologist.

Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase lb/ll study.

M. Ahn, Yi-long Wu, E. Felip, 2014 .

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Edward S. Kim, Keunchil Park, F. de Marinis, 2022, Frontiers in Oncology.

Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

N. Girard, R. Govindan, Keunchil Park, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib

P. Jänne, F. Shepherd, J. Yang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017, The Lancet. Respiratory medicine.

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

M. Ahn, Dong-Wan Kim, J. Yang, 2016, Science Translational Medicine.

Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis.

J. Shih, R. Rosell, Pan‐Chyr Yang, 2016, Lung cancer.

Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL

S. Steinberg, S. Rosenberg, J. Yang, 2010, Journal of immunotherapy.

Tumor Regression and Autoimmunity in Patients Treated With Cytotoxic T Lymphocyte–Associated Antigen 4 Blockade and Interleukin 2: A Phase I/II Study

S. Rosenberg, J. Yang, A. Maker, 2005, Annals of Surgical Oncology.

Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study.

A. K. Srivastava, M. Raffeld, S. Rosenberg, 2017, The Lancet. Oncology.

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

A. Feldman, S. Rosenberg, I. Lowy, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer.

T. Owonikoko, J. Yang, Bassel Nazha, 2020, Future oncology.

Effective Treatment Of Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma With Autologous T Cells Genetically-Engineered To Express An Anti-CD19 Chimeric Antigen Receptor

Sadik H. Kassim, S. Rosenberg, J. Yang, 2013 .

A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors

G. Shapiro, E. Kwak, J. Yang, 2014, Investigational New Drugs.

A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non–Small‐Cell Lung Cancer

Keunchil Park, B. Han, T. Mok, 2018, Clinical lung cancer.

Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor–resistant non-small cell lung cancer (NSCLC).

P. Jänne, M. Ranson, M. Ahn, 2014 .

Survival of Patients with Small Cell Lung Carcinoma in Taiwan

M. Lai, J. Yang, W. Shau, 2012, Oncology.

INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer

Keunchil Park, T. Mok, Yi-long Wu, 2011, BMC Cancer.

Small-cell lung cancer treatment: where is the target?

J. Yang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy

S. Rosenberg, J. Butman, J. Yang, 2010, Clinical Cancer Research.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

W. Wilson, S. Rosenberg, R. Morgan, 2012, Blood.

Adoptive cell therapy targeting common p53 neoantigens in human solid cancers

Chuong D. Hoang, C. Hoang, J. Gartner, 2021 .

The adoptive transfer of cultured T cells for patients with metastatic melanoma.

J. Yang, 2013, Clinics in dermatology.

Experience with the Use of High‐Dose Interleukin‐2 in the Treatment of 652 Cancer Patients

W. Linehan, S. Rosenberg, M. Lotze, 1989, Annals of surgery.

PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.

I. Marschner, J. Yang, W. Cooper, 2022, Future oncology.

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans

A. K. Srivastava, S. Rosenberg, J. Yang, 2014, Clinical Cancer Research.

Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

J. Yang, P. Robbins, K. Hanada, 2012, Cancer research.

Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma.

J. Yang, S. Feldman, Yangbing Zhao, 2011, Journal of immunological methods.

Destruction TumorUbiquitously while Mediating Specific T Cells Traffic Indiscriminately and + CD 8 Vaccine-Stimulated , Adoptively Transferred

C. Klebanoff, J. Yang, N. Restifo, 2004 .

Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma

S. Rosenberg, J. Yang, D. White, 2021, Clinical Cancer Research.

Treatment of metastatic uveal melanoma with adoptive transfer of tumor infiltrating lymphocytes: a single-center phase 2 study

A. K. Srivastava, M. Raffeld, S. Rosenberg, 2017 .

Adoptive T-Cell Therapy for Cancer.

S. Rosenberg, J. Yang, 2016, Advances in immunology.

Melanoma vaccines.

J. Yang, 2011, Cancer journal.

Assessment of Ovarian Function After Preparative Chemotherapy and Total Body Radiation for Adoptive Cell Therapy

S. Rosenberg, J. Yang, D. White, 2011, Journal of immunotherapy.

Selection of CD8+PD-1+ Lymphocytes in Fresh Human Melanomas Enriches for Tumor-reactive T Cells

S. Rosenberg, J. Yang, J. Wunderlich, 2010, Journal of immunotherapy.

T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study

J. Gartner, S. Rosenberg, S. Hewitt, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The ongoing mystery of renal cell cancer

J. Yang, 2021, Cell reports. Medicine.

Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.

Ying Cheng, Keunchil Park, Yi-long Wu, 2020, The Lancet. Respiratory medicine.

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials.

L. Sequist, Keunchil Park, Yi-long Wu, 2019, Lung cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

L. Sequist, K. O'Byrne, T. Mok, 2015, The Lancet. Oncology.

Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT

M. Ahn, J. Yang, R. Cheng, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al.

J. Yang, M. Orlando, T. Puri, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2018, Journal of Cancer.

Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer

J. Yang, J. Cheng, Kuan-Yu Chen, 2016, Case Reports in Oncology.

Best Response According to RECIST During First‐line EGFR‐TKI Treatment Predicts Survival in EGFR Mutation‐positive Non–Small‐cell Lung Cancer Patients

Jih-Hsiang Lee, J. Shih, J. Yang, 2018, Clinical lung cancer.

Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors.

You Won Lee, Jae Woo Choi, J. Shih, 2018, Cancer research.

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

Jie Yang, Jih-Hsiang Lee, N. Strelkowa, 2020, British Journal of Cancer.

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation–Positive Advanced NSCLC: Findings From a Global Named Patient Use Program

J. Shih, S. Peters, G. Chang, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer

R. Govindan, A. Dingemans, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers

S. Rosenberg, C. Klebanoff, J. Yang, 2018, Clinical Cancer Research.

Durable remissions in two adult patients with Burkitt lymphoma following anti-CD19 CAR T-cell therapy: a single center experience

S. Rosenberg, J. Yang, M. Ahlman, 2022, Leukemia & lymphoma.

Real-World or Controlled Clinical Trial Data in Real-World Practice.

J. Yang, Ting-Hui Wu, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Erratum: Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer (J Natl Cancer Inst (1993) 85 (622-632))

S. Rosenberg, M. Lotze, J. Yang, 1993 .

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of immunotherapy.

Viruses Encoding the Anchor-modified gp 100 Melanoma Antigen Can Generate Antitumor Immune Responses in Patients with Metastatic Melanoma

S. Rosenberg, P. Hwu, J. Yang, 2003 .

Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study.

T. Chen, J. Yang, L. Lee, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

An antigenic peptide produced by reverse splicing and double asparagine deamidation

S. Rosenberg, J. Yang, P. Robbins, 2011, Proceedings of the National Academy of Sciences.

A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors

Jih-Hsiang Lee, T. Chen, J. Yang, 2019, Investigational New Drugs.

Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE).

Robert W. Hsieh, Melissa L. Johnson, L. Paz-Ares, 2020 .

KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC).

C. Rudin, S. Peters, A. Navarro, 2020 .

Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.

Robert W. Hsieh, Melissa L. Johnson, J. Yang, 2022, The Lancet. Oncology.

Abstract CT190: A multicenter, open-label, single-arm, phase II study: The third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO)

Ping Wang, Ying Cheng, C. Chiu, 2020 .

Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study

J. Ahn, M. Ahn, Dong-Wan Kim, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Neoantigen Identification and Response to Adoptive Cell Transfer in anti PD-1 Naïve and Experienced Patients with Metastatic Melanoma.

J. Gartner, S. Sindiri, S. Rosenberg, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

TNF/TIL Human Gene Therapy Clinical Protocol: Original Protocol, April 23, 1990

W. Anderson, J. Yang, Y. Chiang, 1990 .

IL-17 Secreted by Tumor Reactive T Cells Induces IL-8 Release by Human Renal Cancer Cells

J. Yang, K. Hanada, Qiong J. Wang, 2009, Journal of immunotherapy.

Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells.

K. Cornetta, S. Rosenberg, R. Morgan, 2011, Human gene therapy.

Characterization of a Novel Nonclassical T Cell Clone with Broad Reactivity against Human Renal Cell Carcinomas1

J. Yang, K. Hanada, Qiong J. Wang, 2008, The Journal of Immunology.

190 Patient-derived tumor organoids reveal mechanisms of immune evasion which can guide decisions in adoptive cell therapy for common epithelial cancers

S. Rosenberg, J. Yang, M. Parkhurst, 2021, Journal for ImmunoTherapy of Cancer.

Anti-CD19 chimeric antigen receptor T cells preceded by low-dose chemotherapy to induce remissions of advanced lymphoma.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2016 .

Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.

P. Hwu, J. Yang, Helen Y Wang, 2002, The Journal of clinical investigation.

Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2.

W. Linehan, P. Hwu, J. Mulé, 1992, Human gene therapy.

Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for tumor necrosis factor.

A. Asher, W. Linehan, P. Hwu, 1992, Human gene therapy.

Safety and Efficacy of High-Dose Interleukin-2 Therapy in Patients With Brain Metastases

S. Steinberg, S. Rosenberg, J. Yang, 2002, Journal of immunotherapy.

Durability of Complete Responses in Patients With Metastatic Cancer Treated With High-Dose Interleukin-2. Identification of the Antigens Mediating Response

S. Steinberg, S. Rosenberg, J. Yang, 1999 .

Melanoma Tumor‐Infiltrating Lymphocytes Derived from Four Distinct Anatomic Sites Obtained from a Single Patient: Comparison of Functional Reactivity and Melanoma Antigen Recognition

M. Nishimura, J. Yang, P. Robbins, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

The use of polyethylene glycol‐modified interleukin‐2 (PEG‐IL‐2) in the treatment of patients with metastatic renal cell carcinoma and melanoma

F. Marincola, S. Rosenberg, J. Yang, 1995, Cancer.

Antitumor Efficacy Demonstrate Superior In Vitro and In Vivo High Avidity CTLs for Two Self-Antigens

S. Rosenberg, J. Yang, H. Zeh, 1998 .

Randomized S tudy o f H igh-Dose a nd L ow-Dose I nterleukin-2 in P atients W ith M etastatic R enal C ancer

S. Steinberg, M. Merino, S. Rosenberg, 2003 .

Surgical resection of metastatic renal cell carcinoma and melanoma after response to interleukin‐2‐based immunotherapy

H. Pass, S. Rosenberg, J. Yang, 1992, Cancer.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

24‐Month Overall Survival from KEYNOTE‐021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First‐Line Therapy for Advanced Nonsquamous Non–Small Cell Lung Cancer

L. Sequist, H. Borghaei, S. Jalal, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply.

V. Gebski, J. Yang, Chee Khoon Lee, 2018, JAMA oncology.

Pembrolizumab (pembro; MK-3475) plus platinum doublet chemotherapy (PDC) as front-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 Cohorts A and C.

L. Sequist, H. Borghaei, A. Patnaik, 2015 .

Human Renal Cell Carcinomas Cell Clone with Broad Reactivity against Characterization of a Novel Nonclassical T

J. Yang, K. Hanada, Qiong J. Wang, 2008 .

Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysis.

T. Mok, Yi-long Wu, K. Goto, 2021, Lung cancer.

MSLT-I—response of clinical trial investigators

J. Yang, R. Sherry, 2014, Nature Reviews Clinical Oncology.

A Prospective Randomized Trial Evaluating Colloid Versus Crystalloid Resuscitation in the Treatment of the Vascular Leak Syndrome Associated with Interleukin‐2 Therapy

S. Steinberg, S. Rosenberg, M. Lotze, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

S. Rosenberg, I. Lowy, J. Yang, 2010, Journal of immunotherapy.

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer.

T. Yamanaka, M. Ahn, Yi-long Wu, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

M. Ahn, Dong-Wan Kim, J. Yang, 2017 .

The hematologic toxicity of interleukin‐2 in patients with metastatic melanoma and renal cell carcinoma

S. Rosenberg, J. Yang, D. White, 1995, Cancer.

for Combination Metastatic Colorectal Cancer Using 5Fluorouracil, Leucovorin and Interleukin-2

E. Shlasko, S. Rosenberg, J. Yang, 1993 .

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

J. Khan, C. Sahinalp, J. Yang, 2021, Molecular & cellular proteomics : MCP.

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vitespen: a vaccine for renal cancer?

J. Yang, 2008, The Lancet.

Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study.

Yih-Leong Chang, J. Shih, J. Yang, 2017, The Lancet. Respiratory medicine.

Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells

J. Yang, A. Lin, W. Hsu, 2021, Cancers.

Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers

I. Chen, Chiun Hsu, J. Yang, 2014, Supportive Care in Cancer.

Adoptive cellular immunotherapy of cancer in mice using allogeneic T-cells

S. Rosenberg, J. Yang, C. J. Bartels, 2006, Annals of Surgical Oncology.

Enterocolitis in Patients After Antibody Blockade of CTLA-4.

S. Rosenberg, J. Yang, S. Topalian, 2005 .

Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010)

S. Rosenberg, I. Lowy, J. Yang, 2005 .

Characterization of the murine lymphokine-activated killer precursor and effector cell

S. Rosenberg, J. Mulé, J. Yang, 1985 .

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

E. Smit, J. Heymach, Keunchil Park, 2021, Clinical cancer research : an official journal of the American Association for Cancer Research.

Real-world insights into patients with advanced NSCLC and MET alterations

J. Shih, D. Carbone, E. Smit, 2021, Lung cancer.

The Development of Gene Therapy for the Treatment of Cancer

S. Rosenberg, W. Anderson, P. Hwu, 1993, Annals of surgery.

Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).

R. Govindan, J. Ahn, S. Ou, 2015 .

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer.

M. Socinski, R. Govindan, A. Shaw, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Sung Sook Lee, F. Shepherd, Dong-Wan Kim, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First‐Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never‐Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.

J. Shih, Ya-Fang Chen, Pan‐Chyr Yang, 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2014, European journal of cancer.

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2015 .

Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer

J. Shih, Pan‐Chyr Yang, J. Yang, 2014, Journal of Thoracic Oncology.

Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.

Jie Yang, S. Ou, A. Dingemans, 2017, European journal of cancer.

Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer

C. Gridelli, S. Gettinger, M. Ahn, 2018, The New England journal of medicine.

Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma

Thomas A. Davis, Steven A. Rosenberg, Douglas J. Schwartzentruber, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.

John Mao, Francesco M Marincola, F. Marincola, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Chun-Ming Tsai, Dan Massey, Nobuyuki Yamamoto, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma.

S. Rosenberg, W. Wong, R. Nussenblatt, 2009, Ophthalmology.

ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.

M. Rubin, J. Hainsworth, V. Miller, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Sadik H. Kassim, M. Raffeld, S. Rosenberg, 2014, Clinical Cancer Research.

Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes

Jonathan M. Hernandez, Chuong D. Hoang, C. Hoang, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

H. Fine, M. Raffeld, S. Rosenberg, 2019, Journal of immunotherapy.

Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.

S. Rosenberg, C. Klebanoff, J. Yang, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors

J. Yang, N. Restifo, Zhiya Yu, 2015, Cancer Immunology Research.

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.

S. Rosenberg, Alexandria P. Cogdill, R. Morgan, 2009, Blood.

CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors

F. Bova, J. Yang, Jianping Huang, 2019, Nature Communications.

Adoptive T-Cell Therapy for Solid Malignancies.

J. Yang, M. Jafferji, 2019, Surgical oncology clinics of North America.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

D. Douek, S. Rosenberg, S. Darko, 2014, The Journal of clinical investigation.

Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions

S. Rosenberg, Y. Samuels, J. Yang, 2014, Clinical Cancer Research.

A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

Gang Wang, Steven A. Rosenberg, Zelig Eshhar, 2006, Clinical Cancer Research.

Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

S. Steinberg, S. Rosenberg, J. Yang, 2007, Clinical Cancer Research.

Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens.

H. Wakelee, E. Smit, T. Mok, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides

Chih-Hsien Chang, J. Yang, Y. Lo, 2019, Journal of Nanobiotechnology.

Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients.

J. Shih, J. Yang, Jin-Shing Chen, 2019, European journal of cancer.

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer

Min Hwan Kim, You Won Lee, Jae Woo Choi, 2019, EMBO molecular medicine.

Chloroquine Enhances Gefitinib Cytotoxicity in Gefitinib-Resistant Nonsmall Cell Lung Cancer Cells

J. Yang, Ya-Ting Chang, A. Lin, 2015, PloS one.

Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers

J. Gartner, S. Sindiri, V. Hill, 2022, Science.

Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2.

L. Trani, Y. Ohe, E. Felip, 2022, Journal of Clinical Oncology.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

P. Jänne, Gregory Riely, E. Felip, 2021, JAMA oncology.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.

A. Drilon, S. Ou, J. Tabernero, 2020 .

The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases

J. Shih, J. Yang, K. Lan, 2015, PloS one.

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.

M. Ahn, Yi-long Wu, E. Felip, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

J. Gartner, S. Rosenberg, S. Ilyas, 2016, Nature Medicine.

Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression

D. Douek, S. Rosenberg, Y. Samuels, 2013, The Journal of Immunology.

Immune recognition of a human renal cancer antigen through post-translational protein splicing

Jonathan W. Yewdell, J. Yewdell, J. Yang, 2004, Nature.

Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma

C. Sahinalp, J. Yang, U. Guha, 2020, bioRxiv.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor–Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors

Jonathan M. Hernandez, Chuong D. Hoang, C. Hoang, 2022, Cancer immunology research.

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

P. Jänne, Ying Cheng, C. Chiu, 2021 .

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2021, Journal of Clinical Oncology.

The impact of smoking on the effectiveness of immune checkpoint inhibitors — a systematic review and meta-analysis

M. Stockler, I. Marschner, T. Mok, 2020, Acta oncologica.

Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes.

J. Gartner, S. Rosenberg, S. Ilyas, 2019, The Journal of clinical investigation.

Opportunities of circulating tumor DNA in lung cancer.

J. Yang, E. Hsiue, Ting-Hui Wu, 2019, Cancer treatment reviews.

Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis

V. Gebski, R. Herbst, T. Mok, 2017, JAMA oncology.

Scientific Advances in Thoracic Oncology 2016.

H. Groen, C. Rudin, R. Rami-Porta, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Debugging the Black Box.

James C Yang, J. Yang, 2017, Cancer discovery.

Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis

V. Gebski, T. Mok, J. Yang, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The Immunotherapy Roadmap

J. Yang, 2015, Clinical Cancer Research.

Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies.

J. Yang, D. Chen, 2017, Translational research : the journal of laboratory and clinical medicine.

Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.

M. Ahn, Yuh-Min Chen, J. Yang, 2012, Lung cancer.

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response

A. Panchenko, P. Meltzer, G. Giaccone, 2016, Cold Spring Harbor molecular case studies.

Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma

William Pao, Hongbin Ji, Nicolas Girard, 2011, European Respiratory Journal.

Serum endostatin levels are elevated in patients with soft tissue sarcoma

A. Feldman, S. Libutti, J. Yang, 2001, Cancer.

Challenging the Paradigm: EGFR wild-type benefit from an EGFR inhibitor in NSCLC

M. Tsou, J. Yang, D. Ionescu, 2017 .

CD73 Is Regulated by the EGFR-ERK Signaling Pathway in Non-small Cell Lung Cancer

J. Yang, Bin-Chi Liao, S. Griesing, 2021, AntiCancer Research.

The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer

J. Yang, Yuan-Yeh Kuo, Ming-Hung Huang, 2020, Cancers.

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors.

J. Shih, Pan‐Chyr Yang, J. Yang, 2013, Cancer letters.

Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis.

V. Gebski, N. Pavlakis, T. Mitsudomi, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

Masahiro Fukuoka, Haiyi Jiang, Kazuhiko Nakagawa, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

T. Mok, Yi-long Wu, L. Paz-Ares, 2014, Lung cancer.

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

L. Sequist, K. O'Byrne, T. Mok, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diarrhea associated with afatinib: an oral ErbB family blocker

J. Köhler, J. Wolf, J. Yang, 2013, Expert review of anticancer therapy.

Symptom and Quality of Life Benefit of Afatinib in Advanced Non–Small-Cell Lung Cancer Patients Previously Treated with Erlotinib or Gefitinib: Results of a Randomized Phase IIb/III Trial (LUX-Lung 1)

D. Fairclough, V. Miller, J. Yang, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

J. Shih, L. Sequist, S. Ou, 2012, The Lancet. Oncology.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Yan Sun, Lucio Crino, Xiuyu Julie Cong, 2012, The Lancet. Oncology.

Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.

Jih-Hsiang Lee, Yih-Leong Chang, J. Shih, 2019, European journal of cancer.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2016, Oncotarget.

Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer.

C. Paweletz, P. Jänne, J. Barrett, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2017, Lung cancer.

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

M. Raffeld, S. Rosenberg, R. Morgan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

L. Sequist, H. Borghaei, S. Jalal, 2016, The Lancet. Oncology.

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations.

Edward S. Kim, Keunchil Park, J. Yang, 2021, Future oncology.

Efficacy and Safety of Rociletinib Versus Chemotherapy in Patients With EGFR-Mutated NSCLC: The Results of TIGER-3, a Phase 3 Randomized Study

H. Groen, H. Wakelee, E. Smit, 2020, JTO clinical and research reports.

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR

J. Shih, Pan‐Chyr Yang, J. Yang, 2012, Clinical Cancer Research.

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

Seth M Steinberg, S. Steinberg, S. Rosenberg, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.

R. Govindan, J. Ahn, S. Ou, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

C. Rudin, S. Peters, A. Navarro, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1

William Pao, Yumei Pan, Lu Wang, 2012, Proceedings of the National Academy of Sciences.

Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with β-blockers

Edward S. Kim, Diane D. Liu, Jing Wang, 2017, Science Translational Medicine.

Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation

S. Rosenberg, D. Citrin, J. Yang, 2014, Cancer.

Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial

P. Jänne, L. Sequist, J. Wolf, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Journal of Biomedical Science.

Innovations and Challenges in Renal Cancer

S. Goldberg, R. Figlin, W. Linehan, 2004, Clinical Cancer Research.

Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference

S. Goldberg, R. Figlin, W. Linehan, 2004 .

Restoring Host Antitumoral Immunity: How Coregulatory Molecules Are Changing the Approach to the Management of Renal Cell Carcinoma

J. Yang, Haidong Dong, B. Inman, 2009 .

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.

S. Steinberg, M. Merino, S. Rosenberg, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study.

L. Sequist, Gregory Riely, E. Felip, 2020, The Lancet. Respiratory medicine.

Treatment of metastatic human papillomavirus-associated epithelial cancers with adoptive transfer of tumor-infiltrating T cells.

S. Rosenberg, C. Klebanoff, J. Yang, 2018 .

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

S. Rosenberg, J. Yang, N. Restifo, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

S. Rosenberg, J. Yang, D. White, 2012, Clinical Cancer Research.

Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.

F. Cappuzzo, C. Gridelli, F. Hirsch, 2014, Clinical lung cancer.

Pembrolizumab in Combination With Erlotinib or Gefitinib as First‐Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

L. Sequist, A. Patnaik, J. Yang, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Other Paradigms: Growth Rate Constants and Tumor Burden Determined Using Computed Tomography Data Correlate Strongly With the Overall Survival of Patients With Renal Cell Carcinoma

S. Bates, J. Yang, W. Stein, 2009, Cancer journal.

HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.

Richard Sherry, S. Rosenberg, J. Yang, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage.

T. Fojo, S. Bates, J. Yang, 2008, The oncologist.

Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors

J. Yang, Chia‐Chi Lin, A. Cheng, 2019, Targeted Oncology.

Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers.

T. Fojo, S. Bates, J. Yang, 2014, Cancer research.

Angiokinase inhibitors in non-small-cell lung cancer

J. Yang, Chia‐Chi Lin, Wei-Chen Lu, 2015 .

Lung Cancer in Republic of China.

T. Chou, C. Chiu, Yuh-Min Chen, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients

J. Yang, Bin-Chi Liao, S. Griesing, 2019, Therapeutic advances in medical oncology.

The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

J. Shih, J. Yang, Chong-Jen Yu, 2020, Therapeutic advances in medical oncology.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor‐sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non–Small‐cell Lung Cancer

J. Shih, J. Yang, Yi-nan Liu, 2017, Clinical lung cancer.

New data on clinical decisions in NSCLC patients with uncommon EGFR mutations

Chia-Chi Lin, Jih-Hsiang Lee, J. Yang, 2017, Expert review of respiratory medicine.

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.

J. Yang, Chia‐Chi Lin, H. Kao, 2013, Future oncology.

Optimal Management of Patients with Non-Small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations

J. Yang, Chia‐Chi Lin, 2012, Drugs.

Efficacy of Pemetrexed‐Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.

J. Shih, J. Yang, Chong-Jen Yu, 2015, Lung cancer.

Clinical and the Prognostic Characteristics of Lung Adenocarcinoma Patients with ROS1 Fusion in Comparison with Other Driver Mutations in East Asian Populations

Yih-Leong Chang, J. Shih, Pan‐Chyr Yang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

J. Shih, J. Yang, J. Ko, 2019, Lung cancer.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma

Keunchil Park, T. Mok, E. Tan, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

Jie Yang, S. Gettinger, M. Ahn, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mutated RAS: Targeting the “Untargetable” with T Cells

J. Yang, Praveen D. Chatani, P. Chatani, 2019, Clinical Cancer Research.

Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

V. Gebski, S. Thongprasert, D. Chu, 2013, Journal of the National Cancer Institute.

Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2015, Current opinion in oncology.

Clinical outcomes for patients with thymoma and thymic carcinoma after undergoing different front‐line chemotherapy regimens

Yih-Leong Chang, Jang-Ming Lee, J. Yang, 2022, Cancer medicine.

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Keunchil Park, J. Vansteenkiste, J. Yang, 2021, Lung cancer.

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

Keunchil Park, D. Planchard, L. Paz-Ares, 2020, Clinical Cancer Research.

Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer

J. Shih, J. Yang, A. Cheng, 2018, Clinical and translational radiation oncology.

Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first‐line gefitinib, erlotinib and afatinib‐treated non‐small cell lung cancer patients with activating EGFR mutations

Jih-Hsiang Lee, J. Shih, J. Yang, 2019, International journal of cancer.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study.

L. Sequist, H. Borghaei, A. Patnaik, 2018, Lung cancer.

Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

K. O'Byrne, Keunchil Park, T. Mok, 2019, Lung cancer.

Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

Thomas John, Aleksandra, Aleksandra Markovets, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

V. Gebski, I. Marschner, T. Mitsudomi, 2017, Journal of the National Cancer Institute.

Genetic Modifiers of Progression‐Free Survival in Never‐Smoking Lung Adenocarcinoma Patients Treated with First‐Line Tyrosine Kinase Inhibitors

Jih-Hsiang Lee, Chien-Jen Chen, N. Rothman, 2017, American journal of respiratory and critical care medicine.

Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma.

M. Lai, J. Yang, A. Cheng, 2015, Clinical lung cancer.

First-Line Management of EGFR-Mutated Advanced Lung Adenocarcinoma: Recent Developments

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2013, Drugs.

Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.

M. Lai, J. Yang, W. Shau, 2013, European journal of cancer.

Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion

J. Shih, J. Yang, Yi-nan Liu, 2018, Genes, chromosomes & cancer.

EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6

L. Sequist, K. O'Byrne, T. Mok, 2016, British Journal of Cancer.

Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.

M. Ahn, T. Mok, H. Onishi, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Serial Plasma Cell-Free Circulating Tumor DNA Tests Identify Genomic Alterations for Early Prediction of Osimertinib Treatment Outcome in EGFR T790M–Positive NSCLC

Jih-Hsiang Lee, J. Shih, J. Yang, 2020, JTO clinical and research reports.

Safety of gefitinib in non-small cell lung cancer treatment

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Expert opinion on drug safety.

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non–Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis

Jih-Hsiang Lee, J. Shih, J. Yang, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small-Cell Lung Cancer

Jih-Hsiang Lee, J. Shih, Yeun-Chung Chang, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

R. Medema, J. Yang, Chia‐Chi Lin, 2011, Clinical Cancer Research.

BiomarkerAnalysesandFinalOverallSurvivalResultsFroma PhaseIII,Randomized,Open-Label,First-LineStudyofGefitinib VersusCarboplatin/PaclitaxelinClinicallySelectedPatientsWith AdvancedNon-Small-CellLungCancerinAsia(IPASS)

T. Mok, Yi-long Wu, S. Thongprasert, 2011 .

Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)

L. Sequist, K. O'Byrne, T. Mok, 2017, The Patient - Patient-Centered Outcomes Research.

Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer

Jih-Hsiang Lee, J. Yang, Chia‐Chi Lin, 2016, Expert review of molecular diagnostics.

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Keunchil Park, J. Yang, I. Okamoto, 2019, Therapeutic advances in medical oncology.

The Value of Early Depth of Response in Predicting Long‐Term Outcome in EGFR‐Mutant Lung Cancer

V. Gebski, I. Marschner, L. Sequist, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?

J. Yang, Chia‐Chi Lin, Bin-Chi Liao, 2018, Expert opinion on pharmacotherapy.

Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.

Ying Cheng, Pan‐Chyr Yang, J. Yang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice

M. Lai, J. Yang, A. Cheng, 2016, Journal of Cancer.

Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).

T. Mok, Yi-long Wu, N. Saijo, 2014, Lung cancer.

Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study.

J. Yang, Bin-Chi Liao, 2012, Translational lung cancer research.

Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.

J. Friedberg, S. Rosenberg, C. Klebanoff, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI

T. Mitsudomi, T. Mok, J. Yang, 2017, Clinical Drug Investigation.

Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer

N. Hanna, D. Gandara, R. Salgia, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

αβ T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities.

A. Singer, Jinghua Lu, P. Sun, 2012, Immunity.

Genetic Polymorphism of XRCC1 Arg399Gln Is Associated With Survival in Non–Small-Cell Lung Cancer Patients Treated With Gemcitabine/Platinum

J. Shih, Yuh-Min Chen, G. Chang, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of Adjuvant Radiation Therapy in the Treatment of Soft Tissue Sarcoma of the Extremity: 20-year Follow-Up of a Randomized Prospective Trial

S. Steinberg, S. Rosenberg, J. Yang, 2014, Annals of Surgical Oncology.

Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma

S. Rosenberg, J. Yang, A. Maker, 2006, Journal of immunotherapy.

Cytotoxic T lymphocyte-associated antigen 4 blockade with ipilimumab: Long-term follow-up of 179 patients with metastatic melanoma.

S. Rosenberg, J. Yang, D. White, 2010 .

High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinoma

S. Steinberg, S. Rosenberg, J. Yang, 2008, Cancer.

Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L.

M. Ahn, D. Camidge, Geoffrey Liu, 2020 .

Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy

B. Neyns, J. Yang, M. L. Kwong, 2013, Clinical Cancer Research.

Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas

J. Shih, J. Yang, A. Cheng, 2013, Journal of Neuro-Oncology.

Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study.

M. Lai, J. Yang, W. Shau, 2012, The oncologist.

Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma

Sadik H. Kassim, S. Rosenberg, R. Morgan, 2015, Clinical Cancer Research.

Toxicities Associated With Adoptive T-Cell Transfer for Cancer.

J. Yang, James C Yang, 2015, Cancer journal.

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study.

B. Halmos, J. Yang, T. Čufer, 2018, Future oncology.

Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.

J. Yang, K. Hanada, Qiong J. Wang, 2011, Blood.

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

S. Rosenberg, J. Rossi, J. Yang, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

Matthew Grist, P. Jänne, K. Varnäs, 2016, Clinical Cancer Research.

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma

S. Rosenberg, J. Yang, D. Schrump, 2016, Annals of Surgical Oncology.

1235TiP Perioperative pembrolizumab + platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study

M. Tsuboi, H. Wakelee, J. Yang, 2020 .

Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies

P. Jänne, L. Sequist, T. Mitsudomi, 2018, Cancer.

Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines

S. Steinberg, S. Rosenberg, J. Yang, 2008, Clinical Cancer Research.

Liver Resection for Metastatic Melanoma with Postoperative Tumor-Infiltrating Lymphocyte Therapy

S. Steinberg, S. Libutti, S. Rosenberg, 2009, Annals of Surgical Oncology.

Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma.

J. Yang, C. Chu, Yi-Tsz Lin, 2020, Lung cancer.

Acute and long term effects on limb function of combined modality therapy in patients treated with limb sparing surgery for soft tissue sarcoma of the extremity

D. Venzon, S. Rosenberg, T. Delaney, 1990 .

Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients

S. Rosenberg, J. Yang, D. White, 2017, Annals of Surgical Oncology.

SEVEN Adoptive T-Cell Therapy for Cancer

S. Rosenberg, J. Yang, 2016 .

Localization of 111Indium‐labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response

S. Steinberg, S. Rosenberg, B. Pockaj, 1994, Cancer.

Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing

J. Yang, K. Hanada, 2005, Journal of Molecular Medicine.

Reply to "Cancer vaccines: pessimism in check"

S. Rosenberg, J. Yang, N. Restifo, 2004, Nature Medicine.

Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma

Steven A. Rosenberg, Douglas J. Schwartzentruber, S. Rosenberg, 2003, Journal of immunotherapy.

A phase I/II clinical trial of E6 T-cell receptor gene therapy for human papillomavirus (HPV)-associated epithelial cancers.

S. Rosenberg, J. Yang, W. Faquin, 2017 .

Treatment of oligometastases after successful immunotherapy.

J. Yang, R. Sherry, J. Abad, 2006, Seminars in radiation oncology.

Tumor-specific CD4+ Melanoma Tumor-infiltrating Lymphocytes

S. Rosenberg, J. Yang, M. Dudley, 2012, Journal of immunotherapy.

The Envelope Protein of an Endogenous Murine Retrovirus Is a Tumor-Associated T-Cell Antigen for Multiple Murine Tumors

J. Yang, D. Perry-Lalley, 2000, Journal of immunotherapy.

Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines

S. Rosenberg, J. Yang, S. Topalian, 2006, Journal of immunotherapy.

CD70, a novel target of CAR T-cell therapy for gliomas

J. Yang, Y. Shang, D. Lu, 2018, Neuro-oncology.

Generating Renal Cancer-Reactive T Cells Using Dendritic Cells (DCs) to Present Autologous Tumor

J. Yang, T. Karpova, M. Bettinotti, 2005, Journal of immunotherapy.

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes.

S. Rosenberg, R. Morgan, J. Yang, 2013, Blood.

Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Clinical Cancer esearch cer Therapy : Clinical cessful Treatment of Melanoma Brain R astases with Adoptive Cell Therapy

S. Rosenberg, J. Butman, J. Yang, 2010 .

astases with Adoptive Cell Therapy

S. Rosenberg, J. Butman, J. Yang, 2010 .

Tumor Immunology and Immunotherapy

J. Tomlinson, J. Yang, J. Economou, 2012 .

Treatment of Patients with T Cells Expressing a Fully-Human Anti-BCMA CAR with a Heavy-Chain Antigen-Recognition Domain Caused High Rates of Sustained Complete Responses and Relatively Mild Toxicity

S. Rosenberg, T. Lowe, J. Yang, 2021, Blood.

Deep and Durable Remissions of Relapsed Multiple Myeloma on a First-in-Humans Clinical Trial of T Cells Expressing an Anti-B-Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) with a Fully-Human Heavy-Chain-Only Antigen Recognition Domain

S. Rosenberg, J. Yang, M. Stetler-Stevenson, 2020 .

Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Keunchil Park, Y. Ichinose, E. Cho, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit.

K. Cheng, J. Yang, Chong-Jen Yu, 2019, Journal of the Formosan Medical Association = Taiwan yi zhi.

Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy

J. Shih, J. Yang, Chia‐Chi Lin, 2015, Therapeutic advances in medical oncology.

Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer.

R. Govindan, S. Ou, A. Shaw, 2019, Lung cancer.

Enhancing Anticancer Effect of Gefitinib across the Blood–Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80

J. Yang, Y. Lo, A. Lin, 2016, International journal of molecular sciences.

Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial

T. Mok, J. Yang, S. Morita, 2021, JTO clinical and research reports.

Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.

J. Shih, J. Yang, Chong-Jen Yu, 2013, Clinical lung cancer.

Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis.

J. Shih, Pan‐Chyr Yang, J. Yang, 2015, Journal of geriatric oncology.

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

T. Mitsudomi, M. Ahn, Dong-Wan Kim, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC).

T. Yamanaka, M. Ahn, Yi-long Wu, 2016 .

Updated results of a phase 1 study of EGF816, a third-generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2016 .

Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)

R. Herbst, L. Paz-Ares, J. Bendell, 2016 .

Precision Management of Advanced Non-Small Cell Lung Cancer.

Pan‐Chyr Yang, J. Yang, Ching-Yao Yang, 2020, Annual review of medicine.

Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy.

J. Shih, Pan‐Chyr Yang, J. Yang, 2013, Lung cancer.

Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review.

Chong-Jen Yu, Jin-Yuan Shih, J. Shih, 2016, Clinical lung cancer.

First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.

L. Sequist, Gregory Riely, E. Felip, 2015 .

Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

L. Sequist, H. Borghaei, A. Patnaik, 2016 .

Circulating Exosomal Integrin β3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study

J. Yang, J. Cheng, F. Hsu, 2021, Cancers.

First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial.

Chun-Ming Tsai, J. Yang, Jin-Hyoung Kang, 2016, Clinical lung cancer.

Bevacizumab for Patients with Metastatic Renal Cancer

J. Yang, 2004, Clinical Cancer Research.

Abstract 127: Single cell mapping of tumor infiltrating lymphocytes enables neoantigen-reactive T cell identification in metastatic human cancer

S. Rosenberg, J. Yang, Frank J. Lowery, 2021, Tumor Biology.

IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer

J. Shih, Hsuan-Yu Chen, Sung-Liang Yu, 2015, Oncotarget.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study.

B. Halmos, J. Yang, T. Čufer, 2020, Future oncology.

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Ying Cheng, C. Chiu, P. Janne, 2022, Journal of Clinical Oncology.

Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20).

M. Socinski, E. Smit, V. Lee, 2022, Journal of Clinical Oncology.

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Ying Cheng, C. Chiu, P. Janne, 2022, Cancer discovery.

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Gregory Riely, E. Felip, P. Janne, 2021 .

Afatinib for the treatment of non-small cell lung cancer harboring uncommon EGFR mutations: a database of 693 cases

J. Yang, 2021 .

Osimertinib plus selumetinib in EGFR-mutated, non-small cell lung cancer after progression on EGFR-TKIs: A Phase 1b, open-label, multicenter trial (TATTON Part B).

P. Jänne, M. Ahn, Y. Ohe, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial.

Ping Wang, Ying Cheng, C. Chiu, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Nivolumab + chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)

N. Girard, Keunchil Park, T. Mok, 2019, Annals of Oncology.

Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib.

Yih-Leong Chang, J. Shih, Chen‐Tu Wu, 2020, The oncologist.

Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study.

B. Halmos, J. Yang, T. Čufer, 2019, Future oncology.

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

P3.02b-044 Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7: Topic: EGFR Clinical

K. O'Byrne, Keunchil Park, T. Mok, 2017 .

Brigatinib vs Alectinib in Crizotinib-Resistant Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer (ALTA-3).

Geoffrey Liu, J. Yang, S. Popat, 2021, Future oncology.

A Pilot Study of Antiangiogenic Therapy with Bevacizumab and Thalidomide in Patients with Metastatic Renal Cell Carcinoma

S. Steinberg, S. Rosenberg, J. Yang, 2004, Journal of immunotherapy.

Selection of circulating PD-1+ lymphocytes from cancer patients enriches for tumor-reactive and mutation-specific lymphocytes

J. Gartner, S. Rosenberg, S. Ilyas, 2015, Journal of Immunotherapy for Cancer.

Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of Advanced Non-Small-Cell Lung Cancer (ATLAS)

J. Hainsworth, V. Miller, F. Kabbinavar, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials

L. Sequist, K. O'Byrne, T. Mok, 2017 .

Afatinib monotherapy in patients with metastatic squamous cell carcinoma of the lung progressing after erlotinib/gefitinib (E/G) and chemotherapy: Interim subset analysis from a phase III trial.

I. Bondarenko, M. Schuler, J. Yang, 2012 .

Interim analysis of afatinib monotherapy in patients with metastatic NSCLC progressing after chemotherapy and erlotinib/gefitinib (E/G) in a trial of afatinib plus paclitaxel versus investigator’s choice chemotherapy following progression on afatinib monotherapy.

J. Strausz, S. Ou, Keunchil Park, 2012 .

Novel MHC-Independent αβTCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus

B. Engelhardt, A. Singer, Jinghua Lu, 2020, Frontiers in Immunology.

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

S. Rosenberg, J. Yang, S. Topalian, 1994, Journal of the National Cancer Institute.

Radiofrequency Ablation Is Superior to Ethanol Injection in Early-Stage Hepatocellular Carcinoma Irrespective of Tumor Size

M. Lai, J. Yang, Chih-Hung Hsu, 2013, PloS one.

Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.

A. Drilon, B. Solomon, J. Wolf, 2020 .

Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer.

S. Steinberg, W. Linehan, S. Rosenberg, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

Phase I S tudy o f t he I ntravenous A dministration o f Attenuated Salmonella t yphimurium to P atients W ith Metastatic M elanoma

F. Marincola, S. Rosenberg, P. Hwu, 2002 .

Abstract 3725: Combined cytotoxic effects of volasertib and cisplatin in urothelial carcinoma cells

Chia-Chi Lin, Yu-Chieh Tsai, J. Yang, 2012 .

Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours

N. Strelkowa, J. Yang, Chih-Hung Hsu, 2020, British Journal of Cancer.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

A selective ALK inhibitor in ALK-rearranged patients.

J. Yang, 2013, The Lancet. Oncology.

Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene.

J. Shih, J. Yang, Hsu Wu, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Phase I study of an HLA-DPB1*0401-restricted T cell receptor targeting MAGE-A3 for patients with metastatic cancers

S. Rosenberg, C. Klebanoff, J. Yang, 2015, Journal of Immunotherapy for Cancer.

AZD9291, a mutant-selective EGFR inhibitor, as first-line treatment for EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): Results from a phase 1 expansion cohort.

P. Jänne, Y. Ohe, S. Ramalingam, 2015 .

Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research.

Emanuel F Petricoin, J Carl Barrett, W Marston Linehan, 2003, Clinical advances in hematology & oncology : H&O.

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.

S. Rosenberg, J. Yang, S. Topalian, 1994, JAMA.

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

S. Steinberg, S. Rosenberg, J. Yang, 1998, Annals of surgery.

Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas.

J. Yang, G. A. Ohnmacht, J. Yang, 2001, Cancer research.

First-line carboplatin and pemetrexed (CP) with or without pembrolizumab (pembro) for advanced nonsquamous NSCLC: Updated results of KEYNOTE-021 cohort G.

L. Sequist, H. Borghaei, S. Jalal, 2017 .

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.

S. Steinberg, F. Marincola, S. Rosenberg, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

3083 AZD9291 activity in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC) and brain metastases: Data from Phase II studies

P. Jänne, T. Mitsudomi, M. Ahn, 2015 .

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

L. Sequist, E. Smit, E. Felip, 2018 .

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

S. Rosenberg, J. Yang, S. Topalian, 2005, Journal of immunotherapy.

An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.

S. Rosenberg, J. Yang, J. Yang, 1997, The cancer journal from Scientific American.

Next-Generation Approaches to Immuno-Oncology in GI Cancers.

J. Hecht, J. Yang, M. Morelli, 2023, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Genomic profiling of resistant tumor samples following progression on EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor (TKI), in advanced non-small cell lung cancer (NSCLC).

J. Barretina, L. Sequist, Gregory Riely, 2017 .

49 – Management of Toxicities of Targeted Therapies

J. Yang, Chia‐Chi Lin, C. Chu, 2018 .

Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

A. Dingemans, A. Shaw, S. Ou, 2017, British Journal of Cancer.

Pooled mutation analysis for the NP28673 and NP28761 studies of alectinib in ALK+ non-small-cell lung cancer (NSCLC).

Aaron M. Newman, A. Shaw, S. Ou, 2016 .

The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia.

M. Lai, Chiun Hsu, J. Yang, 2015, The oncologist.

Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy.

S. Rosenberg, J. Rossi, J. Yang, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

S. Rosenberg, R. Morgan, J. Yang, 2012, Blood.

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

D. Douek, S. Rosenberg, S. Darko, 2014, The Journal of clinical investigation.

The use of interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma.

S. Rosenberg, J. Yang, S. Topalian, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.